Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “ANTHRANILIC ACID”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 685 records · Page 38Linked to original sources

Toxicology and carcinogenesis studies of naphthalene (cas no. 91-20-3) in F344/N rats (inhalation studies).

UNLABELLED: Naphthalene is used as an intermediate in the synthesis of phthalic and anthranilic acids, naphthols, naphthylamines, sulfonic acid, synthetic resins, celluloid, and hydronaphthalenes; it is also used in the preparation of anthraquinone, indigo, salicylic acid, and 1-naphthyl-N-methylcarbamate insecticide. It is an ingredient in some moth repellants and toilet bowl deodorants; it is also used in veterinary medicine in antiseptics for irrigating animal wounds and as an external medication to control lice on livestock and poultry. Naphthalene was selected for study by the National Toxicology Program because previous inhalation studies with naphthalene in mice were positive and existing studies in rats were either considered inadequate or were conducted via routes other than inhalation. Male and female F344/N rats were exposed to naphthalene (greater than 99% pure) by inhalation for 2 years. Genetic toxicology studies were conducted in Salmonella typhimurium and cultured Chinese hamster ovary cells. 2-YEAR STUDY: Groups of 49 male and 49 female rats were exposed to naphthalene by inhalation at concentrations of 0, 10, 30, or 60 ppm for 6 hours plus T90 (12 minutes) per day, 5 days per week for 105 weeks. Additional groups of nine male and nine female rats were exposed to 10, 30, or 60 ppm for up to 18 months for evaluation of toxicokinetic parameters. Survival, Body Weights, and Gross Observations: The survival of all exposed groups of male and female rats was similar to that of the chamber controls. Mean body weights of all exposed groups of males were less than those of the chamber control group throughout most of the study. Masses were observed in the nose of male and female rats. These masses frequently partially occluded the nasal passages or obliterated the normal architecture of the nasal turbinates. Pathology Findings: The incidences of neuroblastoma of the olfactory epithelium, a rare neoplasm, occurred with positive trends in males and females. Because this neoplasm did not occur in chamber control rats or in male rats exposed to 10 ppm and because this neoplasm has not been seen in the historical chamber control rats in NTP 2-year inhalation studies, the increased incidences of neuroblastoma were considered to be related to naphthalene exposure. In males, the incidences of adenoma of the respiratory epithelium of the nose, another rare neoplasm, occurred with a positive trend and were significantly increased in all exposed groups; none occurred in the chamber controls. In females, these neoplasms occurred in the 30 and 60 ppm groups but not in the chamber control or 10 ppm groups. Because these neoplasms did not occur in the chamber controls and have not been observed in the historical chamber control rats in NTP 2-year inhalation studies, the incidences of nasal adenoma were considered to be related to naphthalene exposure. Increased incidences of nonneoplastic lesions of the nose associated with exposure to naphthalene included atypical hyperplasia, atrophy, chronic inflammation, and hyaline degeneration of the olfactory epithelium; hyperplasia, squamous metaplasia, hyaline degeneration, and goblet cell hyperplasia of the respiratory epithelium; and glandular hyperplasia and squamous metaplasia. Toxicokinetic Results Model: A physiologically based toxicokinetic model was developed to characterize the disposition of inhaled naphthalene in rats. Because of its low vapor pressure and high blood-to-air partition coefficient, essentially all of the naphthalene that is absorbed into the general circulation is metabolized. At the exposure concentrations used in the 2-year study, approximately 20% to 30% of the inhaled dose was metabolized by male and female rats. Naphthalene that was not absorbed during exposure was assumed to be exhaled. The respective estimated daily doses metabolized by rats exposed to 10, 30, or 60 ppm for 6 hours (i.e., the internalized doses) are 3.6, 10.7, and 20.1 mg naphthalene/kg body weight for males and 3.9, 11.4, and 20.6 mg/kg for females. GENETIC TOXICOLOGY: Naphthalene was not mutagenic in any of four strains of Salmonella typhimurium with or without induced liver S9 enzymes. However, in cytogenetic tests with cultured Chinese hamster ovary cells, naphthalene induced significant increases in sister chromatid exchanges with and without metabolic activation (S9) and in chromosomal aberrations with S9. Naphthalene did not induce chromosomal aberrations in the absence of S9 activation. CONCLUSIONS: Under the conditions of this 2-year inhalation study, there was clear evidence of carcinogenic activity of naphthalene in male and female F344/N rats based on increased incidences of respiratory epithelial adenoma and olfactory epithelial neuroblastoma of the nose. In male and female rats, exposure to naphthalene caused significant increases in the incidences of non-neoplstic lesions of the nose.

Administration, Inhalation↗

Multivariate analysis in the pharmacological evaluation of a saluretic compound.

The pharmacological evaluation of the diuretic activity of a compound -- performed measuring the urinary volume and determining its electrolyte content -- may be usefully integrated by a multivariate analysis, in order to: express a general evaluation for each animal in terms of positive or negative response; evaluate the false positive responses of the control group animals and the negative responses in the treated animals on the basis of the general response. An example of application relating to a well-known saluretic, 4-chloro-N-(2-furfuryl)-5-sulfamoyl-anthranilic acid (furosemide), is reported.

Analysis of Variance↗

[Animal experiments on the "dysionic genesis of intrauterine malformations"].

Pregnant rabbits were injected 12 mg 4-chloro-5-sulfamoyl-N-furfuryl-anthranilic acid (furosemide)/kg body weight from the first to the tenth day of pregnancy (o.p.). The serum concentrations of sodium, potassium and calcium were determined on the 1st, 9th and 14th day o.p. The mother rabbits were killed on the 29th day of o.p., their foetuses were removed and the mucous membrane of the uterus was inspected for resorption sites. The foetuses were examined, the skeletons were stained and studied under the microscope. The results of the treated rabbits were compared with those of the control rabbits. The sodium, potassium and calcium concentrations of the treated rabbits were not lowered significantly. The haematocrite did not change during or after the treatment. The mothers gained weight continuously. The rates of resorption and malformation of the treated group were slightly raised.

Abnormalities, Drug-Induced↗

Tryptophan metabolism in the joint diseases.

Tryptophan metabolites through kynurenine pathway and 5-hydroxytryptophan pathway in the synovial fluid, blood and urine of patients with rheumatoid arthritis and those with osteoarthritis were investigated in order to know the specificity of the tryptophan metabolism, especially the role of serotonin in the joint diseases. A metabolic map of tryptophan in the synovial fluid was also made. It was found that tryptophan in rheumatoid arthritis was metabolized mainly to anthranilic acid through kynurenine in the kynurenine pathway, whereas in osteoarthritis the pathway of kynurenic acid and nicotinic acid was characteristic. Otherwise in 5-hydroxytryptophan pathway there were no significant differences in the levels of 5-hydroxytryptamine and 5-hydroxyindole acetic acid in the synovial fluid between rheumatoid arthritis and osteoarthritis but the activity of monoamine oxidase in the synovial fluid was higher in osteoarthritis than in rheumatoid arthritis.

Arthritis, Rheumatoid↗

Toxicology and Carcinogenesis Studies of Naphthalene (CAS No. 91-20-3) in B6C3F1 Mice (Inhalation Studies).

Naphthalene, a white, crystalline powder, is used as a moth repellent and in the manufacture of phthalic and anthranilic acids, naphthylamines, and synthetic resins. The 2-year studies were conducted by exposing groups of male and female B6C3F1 mice to naphthalene (>99% pure) vapor for 6 hours daily, 5 days per week, for 104 weeks. Genetic toxicology studies were conducted in Salmonella typhimurium and Chinese hamster ovary cells. 2-Year Studies: Groups of male and female mice were exposed to atmospheres containing 0 (75 mice per group), 10 (75 mice per group), or 30 ppm (150 mice per group) naphthalene. Mice from each group were included for 14-day hematology evaluations (male: 0 ppm, 5 animals; 10 ppm, 4; 30 ppm, 10; female: 0 ppm, 4; 10 ppm, 5; 30 ppm, 10). Mean body weights of exposed mice were slightly lower than those of controls throughout the studies. Survival of male control mice was significantly less than that of exposed mice; the lower survival was the result of wound trauma and secondary infections related to fighting among the group-housed mice (0 ppm, 26/70, 37%; 10 ppm, 52/69, 75%; 30 ppm, 118/133, 89%). Survival of exposed female mice was similar to that of controls (59/69, 86%; 57/65, 88%; 102/135, 76%). Neoplastic and Nonneoplastic Effects in the 2-Year Studies: No increase in tumor incidence related to naphthalene administration was observed in male mice. In females, the incidence of pulmonary alveolar/bronchiolar adenomas was significantly greater in the high-dose group than in the controls (5/69, 7%; 2/65, 3%; 28/135, 21%). One other high-dose female had an alveolar/bronchiolar carcinoma. The combined incidence of alveolar/ bronchiolar adenomas and carcinomas in the high-dose females was above those for control female B6C3F1 mice from NTP feed, water, and inhalation studies (91/1,166, 7.8%, range 0%-16%). These lung tumors were attributed to naphthalene exposure. Nonneoplastic lesions attributed to naphthalene exposure were observed in the nose and lungs of mice of both sexes. In the nose, naphthalene exposure was associated with an increase in the incidence and severity of chronic inflammation, metaplasia of the olfactory epithelium, and hyperplasia of respiratory epithelium. Chronic inflammation in the lung was associated with chemical exposure. Genetic Toxicology: Naphthalene was negative for the induction of gene mutations in Salmonella typhimurium strains TA100, TA1535, TA1537, and TA98 with and without exogenous metabolic activation (S9). In cytogenetic tests with Chinese hamster ovary cells, naphthalene induced sister chromatid exchanges with and without S9 activation. Exposure to naphthalene induced a significant increase in chromosomal aberrations in Chinese hamster ovary cells in the presence of S9. Conclusions: Under the conditions of these 2-year inhalation studies, there was no evidence of carcinogenic activity of naphthalene in male B6C3F1 mice exposed to 10 or 30 ppm. There was some evidence of carcinogenic activity of naphthalene in female B6C3F1 mice, based on increased incidences of pulmonary alveolar/ bronchiolar adenomas. In both male and female mice, naphthalene caused increased incidences and severity of chronic inflammation, metaplasia of the olfactory epithelium, and hyperplasia of the respiratory epithelium in the nose and chronic inflammation in the lungs. Synonyms: Naphthalin, Naphthene, Tar Camphor

Journal Article↗

Microbial models of mammalian metabolism. N-dealkylation of furosemide to yield the mammalian metabolite CSA using Cunninghamella elegans.

Furosemide (Lasix), a widely used diuretic, is metabolized by the fungus Cunninghamella elegans (ATCC 36112) to 4-chloro-5-sulfamoyl anthranilic acid (CSA), a metabolite also present in mammalian systems. This metabolite was isolated following preparative-scale incubations of C. elegans, and was characterized by comparison with standard CSA using 13C-NMR, mass spectrometry (high-resolution mass spectra, electron impact mass spectra), UV, TLC, and HPLC with fluorescence detection. Because a known complication with furosemide studies is the spontaneous formation of CSA by decomposition of furosemide during incubation, extraction, and/or analysis, a time course study was conducted to determine the rate of CSA formation caused by metabolism vs. the relatively low rate of CSA formation caused by spontaneous decomposition.

Biotransformation↗

Studies on human lens: I. Origin and development of fluorescent pigments.

Fluorescence spectra of normal mature human lenses have been measured and at least eight species with distinct emission characteristics identified. To determine the specific photochemical and photophysical processes responsible for the origin and development of these fluorophores, emission behavior of the products generated by successive irradiation of young human lenses (3-6 y old) as well as of L-tryptophan solution have been systematically monitored. Fluorescent products that resulted from this irradiation were comparable to many of the fluorophores detected in aged lenses, indicating that light plays a major role in the development of these pigments. In addition to photogenerated species, there are other compounds in human lenses, presumably advanced glycosylated end products, with marked fluorescence properties. Several oxidation products of tryptophan including N-formylkynurenine or its derivatives, beta-carboline or its derivatives, and anthranilic acid have been identified in the mature human lens. The development of several photoproducts also was attributed to endogenous ascorbate-mediated Maillard reaction products, which undergo photoconversion by the visible light. Although some of these chromophores could act as photosensitizers, the sensitizing efficiency of many are low. Conversely, the near-UV filtering capability of these colored compounds conceivably could protect the vitreous and retina from development of any photochemical lesion.

Adult↗

Localization of the anti-allergic agent tranilast in the urinary bladder of rats as demonstrated by light microscopic radioautography.

Tranilast (N-(3,4-dimethoxycinnamoyl)anthranilic acid), an anti-allergic drug, has been developed and used for the treatment of anaphylactic hypersensitivity such as bronchial asthma in Japan. Recently, many cases with eosinophilic cystitis associated with administration of this drug have been reported. In a series of studies to elucidate the pathoetiology of this unusual cystitis, the distribution of tranilast in urinary bladder of rats was investigated. Light microscopic radioautography using tritiated tranilast showed that this drug was localized specifically in the transitional epithelial cells of the mucosa and the endothelial cells of venous vessels for a fairly long time after an oral administration. These results should be taken into consideration in further studies of this drug-associated cystitis.

Animals↗

[Changes in the burrowing reflex of mice and rats under the influence of kynurenines].

Behaviour of SHR, C57B1/6 male mice and common albino male rats treated intracerebroventricularly or intraperitoneally with kynurenine, quinolinic, kynurenic, picolinic, xanthurenic, anthranilic acids and nicotinamide, was studied in the dark/light chamber. Quinolinic acid and its precursor kynurenine diminished dark preference, increased the number of transitions between dark and light compartments, diminished locomotion in light compartment. Biogenic amine phenylethylamine with its typical anxiogenic activity, exerted a similar action. Diazepam acted in the opposite way. Noncompetitive antagonist of the NMDA receptors, kynurenic acid, prevented the effect of quinolinic acid. The hole reflex appears to be a useful simple object to study neuroactive endogenous compounds on.

Animals↗

Biopharmaceutical studies of 3-substituted isatin derivatives.

The metabolic fate of isatin hydrazone (Ia), isatin-3-thiosemicarbazone (Ib), isatin-3-semicarbazone (Ic), isatin-3-phenylhydrazone (Id), isatin oxime (Ie) and 3-hydroxy-3-acetonyl oxindole (II) was studied in rabbits. The compounds were administered orally in the dose of 300 mg/kg body wt. Isatin anthranilic acid, tryptophan and nicotinic acid were identified as the major metabolites excreted in urine. The 3-hydroxy-3-acetonyl oxindole (II) gave on additional metabolite, oxindole. The major metabolites were separated and identified unambiguously on thin layer silica gel plate. Metabolic pathways have been proposed to explain the biotransformation of the compounds investigated.

Animals↗

[The influence of drugs on the purine salvage metabolism in human blood cells (author's transl)].

The influence of 1-phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4n-butylpyrazolidine-monohydrate (oxyphenbutazone) and N-(alpha,alpha,alpha-trifluoro-m-tolyl)-anthranilic acid (flufenamic acid) on the purine salvage pathway of erythrocytes and lymphocytes following incubation of heparinized whole blood with the drugs was investigated. As described in earlier experiments in vitro with enzymes derived from cell homogenates, the enzyme activities of whole cells were also decreased. Lymphocytes exhibited a reduction of purine-phosphoribosyltransferase (purine-PRT) activities (adenine-, guanine- and hypoxanthine-PRT) of about 20%. The effect on the enzyme activities in red blood cells was different. The A-PRT-activity was decreased to about 33%, the GH-PRT on the other hand, to about 10%. The possible significance of these results in vivo is discussed.

Erythrocytes↗

[Ambroxol, studies of biotransformation in man and determination in biological samples (author's transl)].

15 mg trans-4-[2-amino-3,5-dibromo-benzyl)-amino]-cyclohexanol-hydrochloride (ambroxol, NA 872) was administered i.v. and orally to healthy volunteers. The metabolic pattern in urine and plasma was similar for both routes of administration. Biotransformation reactions are straightforward, yielding two major products of phage I reactions identified as 6,8-dibromo-3-(trans-4-hydroxycyclohexyl)-1,2,3,4-tetrahydro-quinazoline and 3,5-dibromo-anthranilic acid. These metabolites as well as the parent compound are also converted to conjugates, predominantly glucuronides. Quantification of unlabelled ambroxol in biological fluids is achieved by radiochemical derivatisation with 14C-labelled formaldehyde in imitation of the biotransformation.

Administration, Oral↗

[Effect of furosemide on the hemodynamics of the kidney medulla during salt depletion].

UNLABELLED: In sodium depleted rats cortical and medullary blood flow was studied before and after 4-chloro-N-(2-furylmethyl)-5-sulfamoyl-anthranilic acid (furosemide). 86Rb was used as an indicator of renal hemodynamics. Its activity was assessed in systemic blood and in tissue slices of the kidney. At the beginning of the experiments the animals were loaded p.o. with 1.3 ml/100 g b.w. of isotonic saline. 3 h later a rapid i.v. injection of 50 muCi (=5.6 MBq) 86Rb was given to 12 control and 9 furosemide treated animals. RESULTS: After 0.7 mg/100 g b.w. of furosemide the sodium and water excretion rises to 820% and 860% resp. (p less than 0.0005). Systemic body hematocrit increases from 47 to 49%. The renal cortical blood flow is not influenced by furosemide. Compared with controls there is a decrease in blood flow through the outer medulla from 1.57 +/- 0.65 to 1.00 +/- 0.37 ml/g.min, through the inner medulla from 0.75 +/- 0.30 to 0.59 +/- 0.23 ml/g.min, and through the papillary tips from 0.85 +/- 0.40 to 0.46 +/- 0.18 ml/g.min. However, these hemodynamics changes are not significant. It is concluded that the decrease in renal medullary hemodynamics of furosemide-treated rats is due to a stimulation of the renin-angiotensin system.

Animals↗

[Transformation of L-tryptophan by Rhizobium phaseoli].

Transformation of L-tryptophan was studied in Rhizobium phaseoli 680. The culture was capable of oxidation decarboxylation, transamination and degradation of L-tryptophan. Four metabolites were identified: tryptamine, indolyl-3-pyruvic, indolyl-3-acetic and anthranilic acids. The fifth metabolite has not been yet identified.

Chromatography, Thin Layer↗

A clinical evaluation of N-5' with perennial-type allergic rhinitis--a test by the multi-clinic, intergroup, double-blind comparative method.

N-(3,4-dimethoxycinnamoyl) anthranilic acid (N-5'), a new orally useable mast cell stabilizer, was investigated for its efficacy, safety and usefulness in the treatment of 302 patients with perennial nasal allergy by an intergroup, double-blind comparative test using disodium cromoglycate (DSCG) and an inactive placebo as control. The results indicated that N-5', as a mild mast cell stabilizer, was comparable to DSCG in efficacy and minimum in side effect.

Clinical Trials as Topic↗

Double-blind multicenter studies with meclofenamate sodium in the treatment of rheumatoid arthritis in the United States and Canada.

The therapeutic efficacy of N-(2,6-dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) in the management of rheumatoid arthritis was clearly established in four large, double-blind, controlled multicenter studies in 757 patients. In one study, 200 mg/day of meclofenamate sodium was compared with 300 mg/day and placebo for six weeks. Another compared meclofenamate sodium, 300 mg/day, with acetylsalicylic acid (ASA), 3.6 g/day, for eight weeks. Two other long-term studies compared meclofenamate sodium and ASA, 300 mg/day and 3.6 g/day, respectively, for six months; in one, the patients were allowed to receive concomitant gold salts or steroids, while in the other, they were not. Both objective and subjective measures showed that meclofenamate sodium was as effective as ASA and superior to placebo. Gastrointestinal reactions, most commonly diarrhea, were seen more often with meclofenamate sodium than with ASA or placebo, but withdrawal for adverse reactions did not differ significantly between treatment groups. ASA-associated side effects such as tinnitus and deafness were not experienced by the patients receiving meclofenamate sodium. Meclofenamate sodium is a safe, effective agent for the treatment of rheumatoid arthritis.

Adolescent↗

Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study.

20 patients with an attack of acute gout participated in this double-blind study, ten patients received N-(2,6-dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) and ten indometacin. The median time interval between onset of attack and onset of treatment was 11 h in the meclofenamate sodium group and 14 h in the indometacin group; medication was started with a dose of 200 mg meclofenamate sodium or 25 mg indometacin followed by 100 mg meclofenamate sodium or 25 mg indometacin every 4 h for the first 24 h. Thereafter patients received 100 mg meclofenamate sodium or 50 mg indometacin at 8-h intervals for 6 days. Similar improvement of intensity of spontaneous pain, swelling, tenderness of touch and degree of limitation of function was noted in patients of both treatment groups. This improvement could already be noted after 24 h of treatment and was sustained throughout the medication period and follow-up period. Adverse reactions were reported by 2 patients in the meclofenamate sodium group and by 5 patients in the indometacin group. The results of this double-blind study indicate that meclofenamate sodium in the dose administered was equally effective in relieving pain and inflammation and restoring restricted function in patients with acute gout as indometacin when used in the generally recommended dose for this indication. Meclofenamate sodium, even at these high dosage levels, was better tolerated than indometacin.

Acute Disease↗

Multicenter studies in the United States and Canada of meclofenamate sodium in osteoarthritis of the hip and knee. Double-blind comparison with placebo and long-term experience.

N-(2,6-Dichloro-m-tolyl) anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) was compared to placebo in two controlled multicenter trials of similar design, one in 180 patients with osteoarthritis of the hip and the other in 237 patients with osteoarthritis of the knee. Following one week on placebo to establish a baseline, patients were given meclofenamate sodium (300 mg/day) or placebo for a four-week double-blind controlled period of treatment. Improvement with meclofenamate sodium consistently exceeded that with placebo. In the hip and knee trials, the differences were statistically significant for at least three of the four weekly visits in reduction of pain on walking, pain on starting motion, pain on passive motion, night pain (knee only), and tenderness. Early in the study, statistically significant improvement was also observed in tenderness measures of the knee and fabere measures of hip function. At each weekly observation, significantly better global assessment scores of patient condition were reported by the patients (p less than 0.005) and their physicians (p less than 0.01) in the group receiving meclofenamate sodium in both the hip and knee trials. Overall global improvement was reported in 76% of the patients on drug and 42% of those on placebo. 31% of the patients receiving meclofenamate sodium and 23% receiving placebo reported adverse reactions. Gastrointestinal reactions were more frequent among the patients receiving the drug. The improvement achieved during the double-blind phase was maintained or increased in 359 patients who continued into long-term therapy with meclofenamate sodium. Meclofenamate sodium was judged effective and safe in the treatment of osteoarthritis of the hip and knee.

Adult↗